Pair Name	Platycodin D, Sorafenib
Disease Info	[ICD-11: 2C82.0]	Prostate cancer		Investigative
Biological Phenomena	Inhibition-->Cell proliferation
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	CDK4	hsa1019
	Down-regulation	Expression	CDK6	hsa1021
	Down-regulation	Expression	CCND1	hsa595
	Up-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	FOXO3	hsa2309
	Up-regulation	Expression	BIM	hsa10018
	Up-regulation	Expression	FASLG	hsa356
	Up-regulation	Expression	TNFSF10	hsa8743
In Vitro Model	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
	DU145	Prostate carcinoma	Homo sapiens (Human)	CVCL_0105
In Vivo Model	PC3 cells (shRNA-FOXO3a cells and MOCK cells) were injected subcutaneously into the left inguinal area of nude mice (BALB/c, nu/nu, male, 6-8 weeks old)
Result	The combination of Platycodin D and sorafenib may exert potent anti-cancer effects specifically via FOXO3a